TY - JOUR T1 - Role of N-acetylcysteine(NAC) in preventing development of anti tuberculosis therapy(ATT) induced liver injury in pulmonary tuberculosis(PTB) patients, a simple randomized single blind clinical trial JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.5301 VL - 56 IS - suppl 64 SP - 5301 AU - Sadaf Ahmed AU - Nisar Ahmed Rao Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/5301.abstract N2 - Background: ATT is associated with increased risk of liver injury in PTB patients. NAC reduces the chances of drug induced liver injury(DILI)Aim and Objective: To find out if NAC is useful in preventing ATT induced liver injury in PTB patients or notMaterial and Method: A randomized clinical trail conducted on 162 newly diagnosed PTB patients having age between 18-60 years at OICD Karachi. Patients were randomized into two groups, a control group in which only standard ATT was used and a trail group in which standard ATT regimen and NAC 600mg twice daily was used. Patients followed for 2 months. Baseline laboratory tests including aspartate aminotransferase(AST), alanine aminotransferase(ALT) and bilirubin were evaluated before starting ATT,at the end of 2 weeks,at the end of 2 months or whenever patient was symptomatic of liver injuryResults: Out of 169 enrolled patients 7 dropped out,162 completed the study protocol. 54.3% patients were male and 45.7% were female. Liver injury occurred in 14/81(17.3%) in control group and 1/81(1.2%) in trial group. Most of the liver injury was noted in 2nd week of ATT. AST, ALT and bilirubin were found deranged. It was common 10 (66.7%) in age group 50-60 years. Reported symptoms of liver injury were anorexia in 10 (66.7%), nausea and vomiting in 7 (46.7%), abdominal pain in 2 (13.3%) and jaundice in 3 (20.6%)patients in control group whereas 1 patient of trial group was asymptomatic.Conclusion: NAC is effective in preventing ATT induced liver injury.Method: Liver injury, Pulmonary tuberculosis, Anti tuberculosis therapy, N-acetylcysteine.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 5301.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -